- Home
- BUUU vs CUE Comparison
BUUU vs CUE Comparison
Compare BUUU & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUUU
- CUE
- Stock Information
- Founded
- BUUU 2017
- CUE 2014
- Country
- BUUU Hong Kong
- CUE United States
- Employees
- BUUU N/A
- CUE N/A
- Industry
- BUUU Services-Misc. Amusement & Recreation
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- BUUU Consumer Discretionary
- CUE Health Care
- Exchange
- BUUU Nasdaq
- CUE Nasdaq
- Market Cap
- BUUU 68.1M
- CUE 59.5M
- IPO Year
- BUUU 2025
- CUE 2018
- Fundamental
- Price
- BUUU $5.40
- CUE $0.83
- Analyst Decision
- BUUU
- CUE Strong Buy
- Analyst Count
- BUUU 0
- CUE 2
- Target Price
- BUUU N/A
- CUE $3.00
- AVG Volume (30 Days)
- BUUU 500.6K
- CUE 120.6K
- Earning Date
- BUUU 01-01-0001
- CUE 08-12-2025
- Dividend Yield
- BUUU N/A
- CUE N/A
- EPS Growth
- BUUU N/A
- CUE N/A
- EPS
- BUUU 0.04
- CUE N/A
- Revenue
- BUUU $5,754,120.00
- CUE $8,286,000.00
- Revenue This Year
- BUUU N/A
- CUE N/A
- Revenue Next Year
- BUUU N/A
- CUE $23.84
- P/E Ratio
- BUUU $139.77
- CUE N/A
- Revenue Growth
- BUUU 64.23
- CUE N/A
- 52 Week Low
- BUUU $3.67
- CUE $0.45
- 52 Week High
- BUUU $5.55
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- BUUU N/A
- CUE 53.58
- Support Level
- BUUU N/A
- CUE $0.77
- Resistance Level
- BUUU N/A
- CUE $0.84
- Average True Range (ATR)
- BUUU 0.00
- CUE 0.06
- MACD
- BUUU 0.00
- CUE -0.00
- Stochastic Oscillator
- BUUU 0.00
- CUE 71.90
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.